title: mTOR inhibitors in cancer therapy.
abstract: The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer.
authors.affiliation: Markey Cancer Center, University of Kentucky, Lexington, KY 40536-0093, USA.
authors.forename: Yekaterina Y
authors.initials: YY
authors.lastname: Zaytseva
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Valentino
authors.forename: Pat
authors.initials: P
authors.lastname: Gulhati
authors.forename: B Mark
authors.initials: BM
authors.lastname: Evers
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D015398:Signal Transduction; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D000081082:Phosphoinositide-3 Kinase Inhibitors; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases